Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K)

被引:0
|
作者
Saad, Abdulaziz Ahmed A. [1 ]
Zhang, Fan [2 ]
Mohammed, Eyad Abdulwhab H. [1 ]
Wu, Xin'an [2 ]
机构
[1] Lanzhou Univ, Sch Pharm, Lanzhou 730000, Peoples R China
[2] Lanzhou Univ, Hosp 1, Dept Pharm, Lanzhou 730000, Peoples R China
关键词
drug-drug interaction; nephrotoxicity; organic cation transporter 2; multidrug and toxin extrusion 1 and 2-K; CISPLATIN-INDUCED NEPHROTOXICITY; SOLUTE CARRIER TRANSPORTERS; EXTRUSION PROTEINS; KIDNEY INJURY; TARGETED DISRUPTION; GENETIC-VARIANTS; METFORMIN; MATE1; CIMETIDINE; PHARMACOKINETICS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The organic cation transporter 2 (OCT2) belongs to the SLC22 family, while the multidrug and toxin extrusion 1 and 2-K (1VIATE1/MATE2-K) belong to the SLC47 family, are localized to the basolateral and apical membrane of human renal proximal tubular epithelial cells, respectively. They are polyspecific transporters that enable the transit of structurally diversified drugs with overlapping selectivity across plasma membranes. OCT2 and MATE1/2-K are critically involved in renal secretion, pharmacokinetics (PK), and toxicity of cationic drugs. Drug-drug interactions (DDIs) at OCT2 and/or MATEI/2-K have been shown to result in clinical impacts on PK, therapeutic efficacy and are probably involved in the renal accumulation of drugs. Sites of OCT2 and MATE1/2-K expression and function play an essential role in the pharmacokinetics and toxicity of drugs, such as cisplatin. Thus, knowing the sites (basolateral vs. apical) of the interaction of two drugs at transporters is essential to understanding whether this interaction helps prevent or enhance drug-induced nephrotoxicity. In this work, an overview of OCT2 and MATE1/2-K is presented. Primary structure, membrane location, functional properties, and clinical impact of OCT2 and MATE1/2-K are presented. In addition, clinical aspects of DDIs in OCT2 and MATE1/2-K and their involvement in drug nephrotoxicity are compiled.
引用
收藏
页码:382 / 393
页数:12
相关论文
共 50 条
  • [1] Challenges and Opportunities for Improved Drug-Drug Interaction Predictions for Renal OCT2 and MATE1/2-K Transporters
    Krishnan, Srinivasan
    Ramsden, Diane
    Ferguson, Douglas
    Stahl, Simone H.
    Wang, Joanne
    McGinnity, Dermot F.
    Hariparsad, Niresh
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (03) : 562 - 572
  • [2] Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine
    Mueller, Fabian
    Koenig, Joerg
    Hoier, Eva
    Mandery, Kathrin
    Fromm, Martin F.
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (06) : 808 - 815
  • [3] Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin
    Sauzay, C.
    White-Koning, M.
    Hennebelle, I.
    Deluche, T.
    Delmas, C.
    Imbs, D. C.
    Chatelut, E.
    Thomas, F.
    PHARMACOLOGICAL RESEARCH, 2016, 110 : 89 - 95
  • [4] Multidrug and Toxin Extruder Proteins MATE1 and MATE2-K
    Astorga, Bethzaida
    Ekins, Sean
    Morales, Mark
    Wright, Stephen H.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (03): : 743 - 755
  • [5] N-Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug-Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2-K)
    Ito, S.
    Kusuhara, H.
    Kumagai, Y.
    Moriyama, Y.
    Inoue, K.
    Kondo, T.
    Nakayama, H.
    Horita, S.
    Tanabe, K.
    Yuasa, H.
    Sugiyama, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (05) : 635 - 641
  • [6] Prediction of Clinical Drug-Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)
    Kikuchi, Ryota
    Lao, Yanbin
    Bow, Daniel A. J.
    Chiou, William J.
    Andracki, Mark E.
    Carr, Robert A.
    Voorman, Richard L.
    De Morais, Sonia M.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (12) : 4426 - 4432
  • [7] Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters
    Tanihara, Yuko
    Masuda, Satohiro
    Sato, Tomoko
    Katsura, Toshiya
    Oyawa, Osamu
    Inui, Ken-ichi
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (02) : 359 - 371
  • [8] Validation of MATE1 and MATE2-K mediated uptake of metformin in comparison to MPP and the interaction of MATE2-K with antineoplastic agents
    Mueller, J.
    Kuehne, A.
    Floerl, S.
    Burckhardt, G.
    Hagos, Y.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S61 - S61
  • [9] Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia
    Nishizawa, Kei
    Yoda, Noriaki
    Morokado, Fumi
    Komori, Hisakazu
    Nakanishi, Takeo
    Tamai, Ikumi
    PLOS ONE, 2019, 14 (04):
  • [10] FAMPRIDINE IS A SUBSTRATE AND INHIBITOR OF HUMAN OCT2, BUT NOT MATE1 AND MATE2K
    Rowbottom, Christopher
    Boiselle, Carri
    Gan, Lawrence
    Bohnert, Tonika
    Xiao, Guangqing
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S90 - S90